2 terminated, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow GlycoMimetics Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Uproleselan, Placebo - Acute Myeloid Leukemia | Phase 3 | Terminated | GlycoMimetics Incorporated | 388 | 2018-10-15 | 2024-07-29 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
| Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Rivipansel, Placebo - Anemia, Sickle Cell | Phase 3 | Completed | Biossil Inc. | 345 | 2015-06-17 | 2025-03-11 |
Anemia, Sickle Cell (2) · Vaso-Occlusive Crises (2) · Leukemia, Myeloid, Acute (1)
rivipansel (2) · uproleselan (1)
Canada (3) · United States (3) · Australia (1) · France (1) · Ireland (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Daniel J DeAngelo, MD, PhD (1)